Affimed develops TandAbs and Trispecific Abs for substantially increasing the efficacy and extend the therapeutic window by three proprietary platforms
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Early stage mab company, lead product AFM 13 for HL in Phase II trials.